Latest News & Features
Americas
Existing portfolios should be carefully reviewed and care must be taken in drafting new patent applications to withstand section 101 scrutiny in the US, as Judith Kim, director, and Scott Schaller, of counsel, at Sterne Kessler Goldstein & Fox, describe. 30 January 2015
Americas
Maximising the strength of patent protection should be an important objective of any R&D pharma company. Christine Goddard and Janis Fraser of law firm Fish & Richardson offer their six top tips for success. 19 December 2014
Big Pharma
A decision by the CJEU on a Latvian case should make it easier in the future to challenge an MA granted for a generic version of a reference product, as Trevor Cook of WilmerHale explains. 19 December 2014
Europe
Bringing a ‘repurposed’ drug to market requires a clear patent strategy, but clarity is unfortunately lacking in this field, say Simon Kremer and Rachel Jones of law firm Mewburn Ellis. 19 December 2014
Genetics
Does the coming into force of the Nagoya Protocol represent an overdue step in the right direction towards fairness, or more red tape and unattainable expectations? Charles Brabin, a non-practising barrister, sifts through the complexities. 28 November 2014
Big Pharma
By facilitating public access to the work being done, universities face the challenge of maintaining a balance between being transparent and commercialising IP. LSIPR spoke to the head of the University of Manchester IP about walking the fine line. 28 November 2014
Big Pharma
With its roots stretching back to oil company Shell, Crystallics underpins pharmaceutical research and development by investigating the crystalline structures of drugs and potential drug compounds. LSIPR reports. 28 November 2014
Americas
The US Supreme Court has now heard arguments in the appeal of Teva v Sandoz from the US Court of Appeals for the Federal Circuit. This could fundamentally change how patent decisions are reviewed by the Federal Circuit and the deference given to district court rulings, says Felicia Boyd of Barnes & Thornburg. 27 November 2014
Big Pharma
There still are some cultural, legal and procedural barriers that must be overcome before the potential of Brazil’s life sciences sector can be realised, as Gabriel Di Blasi and Mellina Mamede of Di Blasi, Parente & Associados explain. 27 November 2014
article
The Indian Patent Office has issued guidelines aimed at bringing together the intentions of the Patents Act and the Biological Diversity Act, but this has posed serious challenges in obtaining patent protection, say Ranjna Mehta-Dutt and Neha Srivastava of Remfry & Sagar. 27 November 2014